Long-term Non-interventional Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

  • End date
    Dec 28, 2037
  • participants needed
  • sponsor
    Fate Therapeutics
Updated on 28 October 2021


Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study.

The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.


This is a multicenter, non-interventional, observation study designed to provide long-term safety and efficacy data on subjects who have participated in a prior Fate Therapeutics interventional study of FT500 cellular immunotherapy. Subjects will be contacted every six months ( one month), beginning six months after subject completion or withdrawal from the FT500-101 study.

Condition Gastric Carcinoma, Islet Ce417ll Cancer, carcinoma of the cervix uteri, pancreatic cancers, Colon cancer; rectal cancer, squamous cell cancer, Renal Cancer, Renal Cell Cancer, Malignant neoplasm of kidney, Urothelial Carcinoma, Squamous cell carcinoma, Vulvar Dysplasia and Carcinoma, head and neck cancer, Small Cell Lung Cancer, Advanced Malignancies, Colorectal Cancer, HEPATIC NEOPLASM, tumors, colorectal, carcinoma of the cervix, Malignant Adenoma, carcinoma of cervix, Uterine Serous Carcinoma, Carcinoma, Non-Hodgkin's Lymphoma, Head and Neck Cancer, Cervical Cancer, Colon Cancer Screening, Liver Cancer, EGFR Positive Solid Tumor, Microsatellite Instability, Neuroendocrine carcinoma, Gastropathy, Neuroendocrine Carcinoma, cancer of the head and neck, cervix cancer, Disorders of cervix NOS, cancer of the cervix, Advanced Malignant Solid Tumor, cervical carcinoma, Non-Small Cell Lung Cancer, epidermoid carcinoma, Squamous Cell Carcinoma, melanoma, Pancreatic Cancer, nsclc, Rectal disorder, cancer, colorectal, Gastric Cancer, Skin Cancer, clear cell renal cell carcinoma, colorectal cancers, cancer, pancreatic, colorectal tumor, Adenocarcinoma, cancer of the pancreas, Advanced Solid Tumor, sclc, small cell carcinoma, Kidney Cancer, Stomach Cancer, small cell carcinoma of the lung, Transitional cell carcinoma, Stomach Discomfort, HEPATOCELLULAR CARCINOMA, gastric cancers, lymphomas, her2-positive breast cancer, Lymphoma, liver cell carcinoma, Rectal Disorders, Metastatic Melanoma, Melanoma, Renal Cell Carcinoma, skin cancer, Lymphoproliferative Disorder, Merkel cell carcinoma, her2/neu-positive breast cancer, Malignant Melanoma, colorectal neoplasm, cervical cancer, uterine, Uterine Cancer, Lymphoproliferative disorders, HER2 Positive Breast Cancer
Treatment Allogeneic natural killer (NK) cell
Clinical Study IdentifierNCT04106167
SponsorFate Therapeutics
Last Modified on28 October 2021


Yes No Not Sure

Inclusion Criteria

Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study
Subjects who have provided Informed consent prior to their study participation

Exclusion Criteria

Not Applicable
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note